An open-label, multi-centre, dose escalating, phase I/II study to investigate the safety and tolerability of RO5072759 given as monotherapy in patients with CD 20+ malignant disease

Projekt

An open-label, multi-centre, dose escalating, phase I/II study to investigate the safety and tolerability of RO5072759 given as monotherapy in patients with CD 20+ malignant disease

Automatisch geschlossen · 2009 bis 2013

Driessen Christoph, Hitz Felicitas, Hofmann Erika

Art

Klinische Forschung

Reichweite

Multizentrisch, KSSG als teilnehmendes Zentrum

Bereiche

Medizinische Onkologie und Hämatologie, Clinical Trials Unit

Status

Automatisch geschlossen

Start

2009

Ende

2013

Finanzierungsart

Industrie

Studiendesign

Open-label, multi-centre, dose escalating, phase I/randomized phase II study

Schlagwörter (Tags)

RO5072759, MabThera, CD20+, GA101, follicular lymphoma, lymphoma

Weitere Informationen

In der Schweiz sind die Zentren St. Gallen und Zürich beteiligt.

Kurzbeschreibung/Zielsetzung

On open-label, multi-centre, dose escalating, phase I/randomized phase II study to investigate the safety and tolerability of RO 5072759 given as monotherapy in patients with CD20+ malignant disease.
The site KSSG is participating in the phase II part of the study in which RO 5072759 will be randomized against the comparator drug rituximab (MabThera).